Speciality: Rheumatology
Description:
A warm welcome to all the medical professionals in this interesting session of use of JAK inhibitor drugs tofacitinib in rheumatoid arthritis. We have Dr. Sundeep Upadhyaya, Dr. Sonal Mehra, Dr. Chanchal Gera to lead the session.
Immunological pathways play a crucial role in disease management especially in the case of rheumatological disease. Managing rheumatoid arthritis often becomes difficult due to its rate of progression and associated health issues.
The webinar will help in gaining important insights on JAK inhibiting drugs like tofacitinib in controlling rheumatoid arthritis. It is a competitive inhibitor of JAK that binds to adenosine triphosphate in the kinase domain.
Tofacitinib inhibits the process of intracellular signaling from the receptor to the cellular nucleus and inhibits the inflammation process via inhibition of the Janus kinases, which eventually helps in controlling rheumatoid arthritis.
Therefore, listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Beyond What Is Visible in Myelofibrosis?
2.
FDA approves rivanetin as the first-line treatment for lung cancer.
3.
In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.
4.
New First-Line Option for Advanced ALK-Positive Lung Cancer
5.
Certain surgical gestures during prostate removal linked to better sexual function recovery
1.
Tremelimumab: A Potential Breakthrough in Cancer Treatment
2.
The Technological Revolution in Precision Oncology and Tumor Microenvironment Therapy
3.
Artificial Intelligence for Early Cancer Detection Leveraging Multi-Omics: A Comprehensive Review
4.
Harnessing Snake Venom in Hematology: From Toxins to Life-Saving Therapeutics
5.
Unlocking the Potential of SCD: A Comprehensive Guide to Diagnosis and Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
3.
Updates on Standard V/S High Risk Myeloma Treatment
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation